Boryung Pharmaceutical

Boryung Pharmaceutical Co., Ltd. is a South Korean company engaged in the research, development, production, and sale of a wide range of pharmaceutical products. Founded in 1963 and originally involved in wholesale, Boryung transitioned into manufacturing and focuses on developing essential medicines. Its product portfolio includes cardiovascular treatments, antibiotics, anticancer medications, amino acids, cosmetics, gastrointestinal products, and active pharmaceutical ingredients (APIs). Boryung exports its products to approximately 50 countries across six continents, including regions such as Japan, China, Southeast Asia, the Middle East, Europe, South America, and Africa. A notable achievement for the company was the introduction of "Kanarb," the first Angiotensin II Receptor Blocker antihypertensive medication in South Korea in 2011. Boryung is also committed to innovation and exploration in health, as demonstrated by its plans to host the inaugural Care in Space Challenge in 2022, reflecting its ambition to contribute to human health in an evolving technological landscape.